An insight into the dual role of MoS2-based nanocarriers in anticancer drug delivery and therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38552760.
- Also identified by DOI 10.1016/j.actbio.2024.03.019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Over the years, nanomaterials have been exploited as drug delivery systems and therapeutic agents in cancer treatment. Special emphasis has been placed on structure and shape-mediated drug loading and release. Functional materials, including molybdenum disulfide (MoS<sub>2</sub>), have shown promising results because of their tunable structure and unmatched physicochemical properties. Specifically, easy surface functionalization and high drug adsorption ability make them ideal candidates. Although the large surface area of nanosheets/nanoflakes may result in high drug loading, the encapsulation efficiency is better for MoS<sub>2</sub> nanoflower structures. Due to its high targeting abilities, the loading of chemotherapeutic drugs onto MoS<sub>2</sub> may minimize nonspecific cellular death and undesired side effects. Furthermore, due to their strong light-absorption ability, MoS<sub>2</sub> nanostructures have been widely exploited as photothermal and photodynamic therapeutic agents. The unexplored dimensions of cancer therapy, including chemodynamic (Fenton-like reaction) and piezo-catalytic (ultrasound-mediated reactive oxygen generation), have been recently unlocked, in which the catalytic properties of MoS<sub>2</sub> are utilized to generate toxic free radicals to eliminate cancer. Intriguingly, combining these therapeutic modalities often results in high therapeutic efficacy at low doses and minimizes side effects. With a plethora of recent studies, a thorough analysis of current findings is crucial. Therefore, this review discusses the major advances in this field of research. A brief commentary on the limitations/future outlook/ethical issues of the clinical translation of MoS<sub>2</sub>-mediated cancer treatments is also deliberated. Overall, in our observations, the MoS<sub>2</sub>-based nanoformulations hold great potential for future cancer therapy applications. STATEMENT OF SIGNIFICANCE: Development of nanomedicines based on MoS<sub>2</sub> has opened new avenues in cancer treatment. The MoS<sub>2</sub> with different morphologies (nanosheet/nanoflower/QDs) has shown promising results in controlled and targeted drug delivery, leading to minimized side effects and increased therapeutic efficacy. While existing reviews have primarily focused on the optical/thermal properties utilized in photodynamic/photothermal therapy, the outstanding catalytic properties of MoS<sub>2</sub> utilized in cancer therapies (chemodynamic/piezo-catalytic) are often overlooked. This review critically highlights and praises/criticizes individual articles reporting the MoS<sub>2</sub>-based nanoplatforms for cancer therapy applications. Additionally, MoS<sub>2</sub>-based combined therapies for synergistic effects are discussed. Furthermore, a brief commentary on the future prospects for clinical translations is also deliberated, which is appealing to various research communities engaged in cancer theranostics and biomedical sciences research.
Medical subject headings
- Molybdenum
- Disulfides
- Antineoplastic Agents
- Neoplasms
- Drug Carriers